Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
Company Announcements

Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials

Sonnet BioTherapeutics Holdings (SONN) just unveiled an update.

Promising results from the Phase 1b trial of SON-080 for chemotherapy-induced peripheral neuropathy (CIPN) have sparked interest in advancing to Phase 2, particularly for treating Diabetic Peripheral Neuropathy (DPN). SON-080 demonstrated tolerability and potential symptom improvement without pro-inflammatory cytokine responses. With conventional treatments often ineffective, SON-080’s progress represents a significant stride in addressing the unmet need for effective neuropathy therapies. The company is now seeking partnerships to initiate a Phase 2 trial, highlighting SON-080’s promise in improving the quality of life for patients with peripheral neuropathy.

Find detailed analytics on SONN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlySonnet BioTherapeutics files to sell common stock, warrants, no amount given
TipRanks Auto-Generated NewsdeskSonnet BioTherapeutics Maintains Nasdaq Listing Compliance
TheFlySonnet BioTherapeutics regains compliance with Nasdaq
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App